Percutaneously implanted devices designed to seal off the left atrial appendage (LAA) have been around for some time, but a recent study of surgical closure of the appendage might have a beneficial ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient was enrolled in the ...

GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the first patient treated with PerQseal ® ...

In the PROTECT AF trial, patients randomized to left atrial appendage closure initially continued taking warfarin and aspirin to promote device endothelialization. At 45 days after the procedure, 86.8 ...

San Francisco, CA and Caesarea, ISRAEL--InSeal Medical Ltd., developer of percutaneous vascular closure devices for large bore punctures, today announced the successful treatment of three patients ...

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of ...

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure ...

Chicago, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The global left atrial appendage closure devices market was valued at US$ 1.98 billion in 2024 and is expected to reach US$ 9.40 billion by 2033, growing at ...

Ra Medical Systems Inc. launched a simple device that holds sutures more securely in place for closure of percutaneous wound sites during cardiac electrophysiology, structural heart and vascular ...

(RTTNews) - Shares of Catheter Precision Inc. (VTAK) are up over 65% at $4.36, following an encouraging regulatory news related to its LockeT wound closure device. LockeT is a suture retention device ...